Abstract:Background:Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening hyperinflammatory syndrome induced by aberrantly activated myeloid and T cells. Primary or familial HLH (pHLH) is a genetic disorder that typically presents in young children. Secondary HLH (sHLH), which can occur at any age but is most common in adults, is triggered by infection, autoimmune disease, malignancy, or other conditions. Without treatment, HLH is universally fatal; even with existing etoposide-based regimens, survival remains low, particularly for malignancy-associated sHLH. There are no approved therapies specifically for sHLH, and most of our understanding of HLH diagnosis comes from studies of pHLH. The aim of this study is to assemble historical cohorts of sHLH patients from two, large US medical systems to better understand and refine the sHLH clinical definition, characterize demographic, clinical, and treatment characteristics, and compare survival and healthcare resource utilization (HRU) of the cohorts to matched comparison groups. Preliminary findings on the identification of sHLH patients at one US site were previously described [Broome et al., Blood (2022) 140 (Supplement 1): 5490-5491]. Data on sHLH patient identification at both sites are presented here. Methods: Two Electronic Medical Record (EMR) systems were queried to identify potential patients (site 1: 2009-May 2022 with no age restrictions and site 2: 2006-2022 patients >18 years of age). Three methods were developed for patient identification. Method 1 identified patients with any mention of an HLH-related ICD code (ICD-9 288.4; ICD-10 D76.1, D76.2, D76.3). Method 2 identified patients with combinations of an elevated ferritin value (1,000-10,000 ng/mL or >10,000 ng/mL) or a sCD25 test (predictive markers of malignancy-associated sHLH from the Optimized HLH Inflammatory [OHI] index). Method 3 identified patients with etoposide and dexamethasone treatment, removing patients receiving this treatment as part of a chemotherapy regimen. Full chart review of some cohorts was not logistically feasible because of their size (no ferritin >1,000 AND any sCD25 test, ferritin >10,000 AND no sCD25 test, and etoposide and dexamethasone treatment); in these instances, patient records were screened for a mention of HLH or MAS. At each site, one clinician reviewed all charts, and a second clinician reviewed a random sample. HLH diagnosis was assigned based on expert judgement, and all diagnostic conflicts were resolved between the two clinicians. Clinical and diagnostic data on sHLH patients were pulled from the EMR by the reviewing clinician. Results: 528 patients were identified at site 1 via the three methods and their charts were reviewed confirming 65 patients with sHLH. Likewise, among 714 charts reviewed at site 2, 188 patients were confirmed with sHLH. Among all patients with an ICD code (Method 1), 17% (56/327) were determined to have sHLH at site 1 and 33% (162/488) at site 2. Among patients reviewed with ferritin/sCD25 features (Method 2), 4% (9/200) were determined to have sHLH at site 1 and 11% (25/212) at site 2. Among patients reviewed with Method 3, 0% (0/1) were determined to have sHLH at site 1, and site 2 data were not available. (See Table 1) Additional analyses on clinical and treatment characteristics of the sHLH cohorts and survival/HRU comparisons will be presented. Conclusions: Since HLH is a rare, heterogeneous, and complex disease to diagnose and treat, HLH-related ICD codes may not accurately and sufficiently capture the spectrum of HLH patients in EMRs.Clinical indicators of disease were essential for identifying additional patients with this rare disorder. The general consistency of the findings between the two study sites supports the application of this patient identification algorithm across diverse medical centers.

Hyper IgM Syndrome: a Report from the USIDNET Registry

X-linked Hyper-Igm Syndrome with Eosinophilia in a Male Child: A Case Report

Cryptococcal Meningitis and Post-Infectious Inflammatory Response Syndrome in a Patient With X-Linked Hyper IgM Syndrome: A Case Report and Review of the Literature

Novel Mutations in Hyper-Igm Syndrome Type 2 and X-linked Agammaglobulinemia Detected in Three Patients with Primary Immunodeficiency Disease.

A Novel CD40LG Mutation Causing X‑linked Hyper-Igm Syndrome

X-linked Hyper-IgM Syndrome: A Phenotype of Crohn's Disease with Hemophagocytic Lymphohistiocytosis

Clinical follow-up studies of pediatric idiopathic pulmonary hemosiderosis

A Case Report of X-Linked Hyperimmunoglobulin M Syndrome with Lipoma Arborescens of Knees

H syndrome treated with Tocilizumab: two case reports and literature review

[Hyper-IgE syndrome in adults characterized by disseminated mixed infection: a case report and literature review].

Dedicator of Cytokinesis 8 Deficiency and Hyperimmunoglobulin E Syndrome: A Case Report.

Clinical Manifestations and Genetic Analysis of 17 Patients with Autosomal Dominant Hyper-IgE Syndrome in Mainland China: New Reports and a Literature Review

The Identification and Characterization of Retrospective Cohorts of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Patients in the United States

Hypergammaglobulinemia D and Periodic Fever Syndrome (HIDS) in a 3-year-old Patient from Puerto Rico

Challenges in diagnosing and managing hyper-IgE syndrome in a resource-limited setting: a case report

Selective IgM deficiency: evaluation of 75 patients according to different diagnostic criteria

Clinical and immunological features of four patients with activation‐induced cytidine deaminase deficiency: Renal amyloidosis and other presentations

Diagnostic Value Of Serum Immunoglobulinaemia D Level In Patients With A Clinical Suspicion Of Hyper Igd Syndrome

Allogeneic Hematopoietic Stem Cell Transplantation in Immunodeficiency-Centromeric Instability-Facial Dysmorphism (ICF) Syndrome: an EBMT/ESID Inborn Errors Working Party Study

Fertility, Pregnancies and Outcomes Reported by Females with Common Variable Immune Deficiency and Hypogammaglobulinemia: Results from an Internet-Based Survey

Clinical Features and Follow-Up of Chinese Patients with Symptomatic Hypogammaglobulinemia in Infancy.